DB-1312
- Generic Name
- DB-1312
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 227
- Registration Number
- NCT06233942
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath